Immunomedics, Inc.,
IMMU today reported a stabilization of disease, as measured by
computed tomography (CT) according to RECIST criteria, in pancreatic cancer
patients with advanced disease and who failed 1-5 prior therapies. In a group
of 13 CT-assessable patients receiving repeated doses of the Company's
investigational antibody-drug conjugate (ADC), IMMU-132, a median
time-to-progression of 12.7 weeks was reported (range 4.3-21.4 weeks), which
is better than the median 8.0 weeks (range 4-36 weeks) estimated from their
last prior therapy.
Results from the ongoing Phase I/II study were presented at the American
Association for Cancer Research Special Conference on Pancreatic Cancer:
Innovations in Research and Treatment by Vincent J. Picozzi Jr., M.D.,
Director of the Pancreas Center of Excellence at the Virginia Mason Medical
Center's Digestive Disease Institute, Seattle, WA.
It is known that in such advanced, highly malignant cancers, responses and
outcome are poorer with each successive treatment. "This is why we are
encouraged that this group of heavily pretreated, advanced pancreatic cancer
patients showed a longer period of disease control compared with their most
recent therapy before entering this trial," Dr. Picozzi stated.
A total of 15 advanced PDC patients who relapsed after a median of 2 prior
therapies (range 1-5) have been enrolled in the multicenter trial. One patient
was not evaluated due to clinical progression, while another patient's CT
assessment is pending. Patients were administered IMMU-132 on days 1 and 8 in
repeated 21-day cycles for up to 8 cycles. IMMU-132 consists of the Company's
proprietary anti-TROP-2 humanized antibody conjugated with a high number of
SN-38 drug molecules by a site-specific linker technology. Preclinical studies
have indicated that a significantly higher amount of SN-38, the active
metabolite of irinotecan, is delivered to human cancers growing in mice than
when high doses of the parent compound, irinotecan, is given.
IMMU-132 was well tolerated by patients, with 2 patients having received more
than 10 doses. Furthermore, despite multiple administrations, none of the
patients developed an antibody response to IMMU-132 or SN-38 to-date. The
major toxicities are similar to irinotecan, such as neutropenia and diarrhea,
but less severe.
"We are encouraged with these early clinical results from IMMU-132 in patients
with advanced pancreatic cancer," said Cynthia L. Sullivan, President and
Chief Executive Officer. "For future clinical development of this ADC in this
indication, we plan to evaluate it in combination with other drugs used
earlier in this disease, since these results suggest that IMMU-132 is active
in pancreatic cancer," Ms. Sullivan added.
The Company will present current Phase I and II results with IMMU-132 in
diverse advanced solid cancers at the forthcoming American Society of Clinical
Oncology annual meeting, including encouraging partial responses by RECIST
criteria in patients with colorectal, triple-negative breast, small-cell and
non-small cell lung, and esophageal cancers.
This study in pancreatic cancer patients was supported in part by Award Number
R43CA171388 from the National Cancer Institute. The content is solely the
responsibility of the Company and does not necessarily represent the official
views of the National Cancer Institute or the National Institutes of Health.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in